

Autoimmunity, Autoantibodies, and Autism Spectrum Disorder

Elizabeth Edmiston, Paul Ashwood, and Judy Van de Water

ABSTRACT

Autism spectrum disorder (ASD) now affects one in 68 births in the United States and is the fastest growing neurodevelopmental disability worldwide. Alarming, for the majority of cases, the causes of ASD are largely unknown, but it is becoming increasingly accepted that ASD is no longer defined simply as a behavioral disorder, but rather as a highly complex and heterogeneous biological disorder. Although research has focused on the identification of genetic abnormalities, emerging studies increasingly suggest that immune dysfunction is a viable risk factor contributing to the neurodevelopmental deficits observed in ASD. This review summarizes the investigations implicating autoimmunity and autoantibodies in ASD.

Keywords: Autism, Autoimmunity, Immune, Maternal autoantibodies, Neurodevelopmental, Pregnancy

<http://dx.doi.org/10.1016/j.biopsych.2016.08.031>

Autism spectrum disorder (ASD) is a highly heterogeneous neurodevelopmental disorder characterized by behavioral, social, and cognitive deficits (1). Since its first description nearly 70 years ago, our understanding of the disorder has changed considerably (2). Although the diagnosis always relies on behavioral domains and symptomology, there are likely multiple biologically defined subgroups within the ASD spectrum (3–7). Specifically, growing evidence supports that maternal immune dysfunction may underlie the behavioral abnormalities observed in a subset of children affected with the disorder (8). Several immunologic risk factors have been described, including genetic associations with immune-related genes (9–16), family history of autoimmune disease (15,17–21), maternal inflammation and infection during pregnancy (22–27), and altered immune responses in the children, and are associated with increased impairments in core and associated features of ASD (28). More specific to this review, maternal antibrain autoantibodies, which are thought to access the fetal compartment during gestation, have been identified as a risk factor for developing ASD and are proposed to contribute to early neurodevelopmental perturbations in the developing fetus (29–31).

THE RELATIONSHIP BETWEEN AUTOIMMUNITY AND ASD

ASD shares many of the features typically recognized in autoimmune disorders; there is a strong familial predisposition and association with immune abnormalities, the genetic predisposition is complex and believed to be polygenic, environmental factors can increase or modulate risk, and there are substantial gender disparities (17,32). Many of the genes implicated in autoimmunity are also clustered within families with ASD. However, although several candidate genes have

been implicated in the disorder, replication of the majority of these findings has been elusive and hints that in addition to genetic factors, environmental influences, such as those observed in autoimmune diseases, may be contributing to the disorder in some cases (33). Further, ASD is four times more prevalent in males, and recent studies suggest the prevalence in boys is closer to 1 in 42 (34). The epidemiological links between autoimmunity and ASD are compelling, and the similarities have spurred several investigators to connect biologically rooted autoimmune disorders with behaviorally defined ASD.

The first investigations supporting the idea that autoimmunity could be etiologically relevant to ASD were described in a 1971 case report that presented on a child with ASD who had a strong family history of autoimmune disorders (35). Since that time, numerous other reports of autoimmune or immune-mediated disorders associated with an increased ASD risk have emerged (15,17–19,36,37). In one of the largest studies to date that included close to 700,000 children, an increased risk, as expressed by an increased risk ratio (IRR), for ASD was observed in mothers with rheumatoid arthritis (RA) (IRR: 1.70) and celiac disease (IRR: 2.97). A familial history of type 1 diabetes (IRR: 1.78) was also found to increase the risk for having a child with ASD (18). Similar results were seen in a recent systematic review and meta-analysis performed by Wu *et al.* (20) (2015), which suggested that a family history of autoimmune disease was associated with a higher risk for having an affected child, and a statistically significant association was observed in families with hypothyroidism, type 1 diabetes, RA, and psoriasis. A similar analysis by Chen *et al.* (21) found that children born to mothers with autoimmune disease were 34% more likely to develop ASD. A genetic predisposition in autoimmune diseases is often attributed to specific major histocompatibility complex haplotypes and polymorphisms in

Table 1. Studies Linking Autoimmunity and ASD

Type of Study	Research Group	Year	Findings
Case Study	Money <i>et al.</i> (35)	1971	Child with ASD had a family history of autoimmune disease
Research Study	Warren <i>et al.</i> (9)	1991	The null allele of the C4B gene and the extended haplotype B44-C30-DR4 is associated with autism
Research Study	Mostafa and Shehab (14)	2010	
Research Study	Warren <i>et al.</i> (10)	1996	The HVR-3 of certain DRP 1 alleles have a very strong association with ASD
Research Study	Torres <i>et al.</i> (11)	2006	The frequency of HLA-A2 alleles was significantly increased in autistic subjects compared with normal allelic frequencies
Research Study	Campbell <i>et al.</i> (12)	2008	The MET promoter variant rs1858830 C allele was associated with ASD
Population Study	Atladóttir <i>et al.</i> (18)	2009	Increased risk for ASD in mothers with rheumatoid arthritis and celiac disease and in families with type 1 diabetes
Systemic Review and Meta-analysis	Wu <i>et al.</i> (20)	2015	A statistically significant association with ASD was observed in families with hypothyroidism, type 1 diabetes, rheumatoid arthritis, and psoriasis
Systemic Review and Meta-analysis	Chen <i>et al.</i> (21)	2016	Children born to mothers with autoimmune disease were 34% more likely to develop ASD

ASD, autism spectrum disorder; HVR-3, third hypervariable region.

genes involved in establishing self-tolerance and immune regulation (38). Similar polymorphisms and associations have been found in ASD. Most notably, studies have correlated the null allele of the C4B gene (9,14), the extended haplotype B44-C30-DR4, the third hypervariable region of certain DRP 1 alleles (10), and HLA-A2 alleles with an increased susceptibility for ASD (11,39). Interestingly, these alleles and haplotypes are also associated with the same aforementioned autoimmune diseases that are linked with an increased risk for having a child with ASD. Another important functional polymorphism that often clusters in families with ASD is a genetic variant that disrupts transcription of the gene encoding the MET receptor tyrosine kinase (12), which has important roles in both immune regulation and neurodevelopment. The similarities between the findings in ASD and autoimmunity suggest an immune-related subtype of ASD (Table 1).

The notion that immune system dysfunction could be a plausible factor in the cause of ASD is derived from the now-recognized importance of the immune system in healthy neurodevelopment and the ability of immune dysregulation to influence patterns of behavior, especially during gestation (28,39–41). Thus, there is growing recognition that the maternal immune response during critical windows of development has a long-lasting impact on neurodevelopmental outcomes.

THE DETECTION OF AUTOANTIBODIES IN ASD

The recognition that maternal antibodies may lead to developmental defects in the fetal nervous system is not novel. Experiments performed in the late 1950s demonstrated that when female mice were immunized with a brain emulsion and later mated, subsequent offspring had gross brain abnormalities, which the author attributed to maternal antibodies directed against the brain and nervous system of the embryos (42). This idea gained favor again in the early 1970s when researchers, concerned that maternal environmental exposures could have detrimental effects on fetal nervous system development, discovered that maternal immunoglobulin G (IgG) was present in fetal cerebral spinal fluid and was able to gain access to the brain during gestation and early life

because of the permissive nature of the blood-brain barrier during that period (43–45). Succeeding experiments by several groups showed that antibrain antibodies could induce behavioral changes in the exposed offspring (46,47). However, it was not until the 1990s that the first studies implicating maternal antibodies in the cause of ASD emerged.

The earliest study performed by Warren *et al.* (48) (1990) confirmed their hypothesis that maternal autoantibodies reactive to proteins displayed on paternal lymphocytes, which are often found in women with a history of miscarriage, are disproportionately observed in mothers with children with ASD. Although sample sizes of the study were small, it prompted other investigators to conduct similar etiological studies into the role of maternal antibodies and aberrant neurodevelopment associated with ASD. Subsequently, a single sample from the serum of a mother with a child with ASD and developmental delay demonstrated that purified antibodies that reacted to mouse neurons resulted in deficits in the exploratory behaviors in the resulting offspring when injected into a dam during gestation (49).

Acknowledging the importance of these pivotal pilot studies, researchers began to expand these endeavors to include larger clinical populations (Table 1). One of the first expanded case-controlled studies published was performed by Braunschweig *et al.* (50) and included equal numbers of children with autism ($n = 61$) and mothers of typically developing children ($n = 62$), along with a subset of mothers who had children with developmental delay ($n = 40$). This study found a significant correlation between the paired maternal antibody reactivity to fetal brain proteins located within the 37- and 73-kDa molecular-weight bands on a human fetal brain immunoblot and a diagnosis of ASD in the child. Further, this reactivity was only in plasma samples obtained from families affected with ASD because reactivity was not seen in families that had typically developing children or children diagnosed with developmental delay (50). In another small study by Zimmerman *et al.* (51), it was shown by immunoblotting that only antibodies from mothers of autistic children recognized fetal rat brain proteins because no antibody reactivity was detected in the control maternal

group, and they were specific to fetal antigens because they did not bind to proteins derived from postnatal and adult rat brains. These reports were closely followed by a study that examined the serum reactivity of 100 mothers of children with ASD and 100 age-matched control mothers and determined that antibody reactivity to fetal brain proteins observed in mothers of children with ASD significantly differed from the control groups (52).

A similar study using banked midpregnancy (prospective) blood samples also observed that maternal autoantibody binding to antigens near 37 and 73 kDa was only found in women whose children later received a diagnosis of ASD (53). Surprisingly, all the aforementioned reports were unable to find a correlation between a family history of autoimmunity and the presence of maternal antibrain antibodies. However, a later study conducted by Heuer *et al.* (54) reported that 95% of mothers with autoantibodies to both the 37- and 73-kDa fetal brain bands (found only in ASD) possessed the *MET C* allele, which provided the first link between a functional immune-related outcome and an ASD susceptibility gene. In this study population, among the 346 mothers of both children with ASD and typically developing children who were negative for the 37- and 73-kDa bands, 101 (29%) were C/C, 154 (45%) were C/G, and 91 (26%) were G/G. Thus, the *MET C* allele appears to confer susceptibility rather than cause the production of these autoantibodies. Furthermore, because this allelic variant was shown to lead to decreased levels of interleukin 10, a crucial anti-inflammatory cytokine, mothers with this allele are hypothesized to be at increased risk for autoimmunity and autoantibody generation, hinting at a potential mechanism behind the loss of self-tolerance in these mothers. The study conducted by Brimberg *et al.* (55) supports this hypothesis because it found not only that mothers of children with ASD preferentially carried autoantibodies to fetal brain tissue, but that these mothers were also significantly more likely to have antinuclear autoantibodies than mothers of typically developing children and mothers of children with ASD who are antibrain autoantibody negative. Interestingly, it was also discovered that mothers with antibrain autoantibodies had an increased incidence of RA and systemic lupus erythematosus, and conversely, antibrain autoantibodies were detected in women with RA, providing additional evidence that brain-reactive maternal autoantibodies are related to autoimmunity (55). Although the

methods for the study by Brimberg *et al.*, in which serum samples were incubated with mouse tissue sections and autoantibodies were detected using immunofluorescence, differed from previous studies using denatured proteins and detecting autoantibodies by immunoblotting, similar results were achieved in that levels of maternal autoantibodies were elevated in mothers of children with ASD. Although the specific maternal antifetal brain antibodies were disproportionately detected in mothers of children with ASD in the earlier studies and were associated with immune dysfunction and autoimmunity, there was still little evidence supporting the notion that maternal autoantibodies could affect behavior at that time.

In order to address the association between maternal autoantibodies and behavior, another large study was conducted by Braunschweig *et al.* (56) that provided further suggestion of a potential role for maternal autoantibodies in ASD behaviors and reported an association between the presence of antifetal brain antibodies in the mother and ASD-related deficits in the child. The study by Braunschweig *et al.* (56) discovered that paired brain (i.e., 37- and 73-kDa bands) reactivity correlated with lower expressive language scores in the child. Additionally, it was noted in a subsequent study that children born to mothers with this antibody-binding pattern also exhibited abnormal brain enlargement when compared with both children with ASD born to mothers who did not harbor antibrain antibodies and typically developing control children (57). Further, reactivity to a band near 39 kDa was later discovered, and paired reactivity to proteins at 39 and 73 kDa correlated with a broader diagnosis of ASD (which was distinct from full autism at that time), as well as increased irritability on the Aberrant Behavioral Checklist scale (56).

In order to understand how these antibrain antibodies could potentially lead to aberrant developmental trajectories, the identity of the proteins corresponding to the 37-, 39-, and 73-kDa bands needed to be elucidated. Studies by our laboratory, which used two-dimensional gel electrophoresis followed by tandem mass spectrometry peptide sequencing, determined that the maternal autoantibodies recognize seven developmentally regulated proteins in the fetal brain that include lactate dehydrogenase A (LDH-A) and B (LDH-B), stress-induced phosphoprotein 1 (STIP1), guanine deaminase,




Figure 1. Fetal brain antigens. The maternal autoantibodies detected in mothers of children affected with autism spectrum disorder bind to fetal brain antigens that are responsible for a critical process in the developing brain.

collapsin response mediator proteins 1 (CRMP1) and 2 (CRMP2), and Y-box binding protein 1 (Figure 1). The antigens recognized by maternal autoantigens are significant because a number of them are critical for normal brain development, specifically processes essential for neuronal migration and neural network formation; guanine deaminase has an integral role in dendritic branching of hippocampal neurons, whereas STIP1, in combination with the cellular prion protein, is responsible for neuritogenesis and increases neuronal survival (58,59). Further, CRMPs 1 to 5 are necessary for proper growth cone collapse and are required for proper cell migration and axon-dendrite specification (60,61). The effects of Y-box binding protein 1 and LDH in neuronal development are more widespread; Y-box binding protein 1 is involved in almost all DNA and messenger RNA-dependent processes and LDH is essential for energy metabolism (62,63). Subsequent experiments using Western blots containing the purified protein targets confirmed these findings, leading to a finding of a 23% incidence of the highly specific antigen reactivity patterns associated with ASD. Further, we characterized behavioral outcomes in the children of autoantibody-positive mothers that associated with the presence of the most common autoantibody pattern, which included combined reactivity to LDH, STIP1, and CRMP1. Combined maternal antibody reactivity to this autoantigen pattern was found in 7% of mothers with children with ASD and correlated with an increase in stereotypic behaviors in the child (64) (Table 2). Maternal autoantibodies are increasingly implicated in the behavioral and cognitive deficits that characterize ASD, but because these studies have been conducted in human participants, it is impossible to determine the mechanism by which these antibodies lead to the symptoms observed in ASD. In order to understand the potential pathogenic role of maternal antibodies, it was necessary to move to experimental animal studies. Moreover, studies are currently underway to elucidate the peptide epitopes on each fetal antigen recognized by the maternal autoantibody-related ASD antibodies because determining the precise binding site(s) of the autoantibodies may offer insight into the etiology and mechanism by which these antibodies mediate changes in behavior.

ANIMAL MODELS OF ASD

It is possible that the maternal antibodies represent purely a biological marker of damage that occurred during gestation and may not necessarily underlie the neurodevelopmental dysfunction detected in ASD. In order to determine whether maternal antibodies are clinically significant and not just an immune epiphenomenon, studies were initiated by several research laboratories using animal models. Typically, in autoimmune diseases in which antibodies are suspected to have a deleterious role, passive transfer studies, in which antibodies are transferred from a diseased animal to a healthy animal, are often used to establish a pathogenic capacity (65,66).

Nonhuman Primate Models

The first animal studies, which used rhesus macaques because of their increased social repertoire and established battery of social tests, demonstrated that the group of monkeys that were prenatally exposed through passive

transfer to IgG purified from mothers of children with ASD had significantly more stereotypic behaviors and higher levels of motor activity when placed in a novel social setting than monkeys treated with IgG from mothers with typically developing children (67). Further, these findings were recently replicated in a larger study using nonhuman primates administered targeted IgG from mothers of children with ASD that was specific for the dominant 37- and 73-kDa band pattern (now known to correspond to LDH, CRMP1, and STIP1). In the second nonhuman primate model, it was observed that offspring treated with IgG from mothers of children with ASD had abnormal social behaviors and enlarged brain volume compared with control IgG-treated animals. They also found that the dams receiving the ASD-associated IgG displayed heightened maternal protectiveness toward their progeny (68). Although these studies were not without limitations, they provide insight into the potential pathological significance of maternal autoantibodies in ASD and how their interaction with fetal brain antigens may alter the course of brain and behavioral development.

Murine Models

Concurrent to the studies conducted in rhesus macaques, researchers revealed similar findings using a murine passive transfer model in which pregnant mice exposed to a single intravenous dose of human maternal plasma predetermined by immunoblotting to be reactive to the 37- and 73-kDa-banding pattern had offspring with increased anxiety and response to stress, along with impaired motor and sensory development (69). This outcome was also seen in a previous study using pooled IgG from mothers of children with ASD, but not based on any 37- or 73-kDa band patterns. The authors determined that the offspring born to dams injected with IgG from mothers with autistic children, and not from mothers with typically developing children, mimicked some of the symptoms seen in ASD, including alterations in sociability and increased activity and anxiety (70). The most recent studies, aiming to further illuminate the mechanism by which maternal autoantibodies alter fetal brain development, transferred human antigen-specific maternal IgG into the cerebral ventricles of embryonic mice. The first of these studies focused on the behavioral outcomes of the exposed offspring. The offspring injected with antibodies reactive to the 37- and 73-kDa-banding pattern had increased stereotypic behaviors and altered social phenotypes reminiscent of the children born to mothers with this brain pattern reactivity (71). In parallel studies, the physiological effects of maternal IgG revealed increased cellular proliferation in the subventricular zone, increased size of adult cortical neurons, and increased adult brain size and weight compared with animals exposed to autoantibody-negative control IgG (72). Although these studies were highly experimental and not representative of a natural exposure, they offer further evidence supporting the role of maternal antibrain antibodies in the incidence of ASD, as well as insight as to the cellular target: radial glial stem cells. Further, because these studies are limited by the passive transfer of IgG during pregnancy at a single time point, our laboratory has recently created an antigen-driven mouse model by breaking tolerance to the specific antigenic

Table 2. Studies Linking Autoantibodies and ASD

Antibody Target	MW	No. in Study	Autoantibody Prevalence in ASD Population	Research Group	Year
Fetal Rat Brain	Low MW bands and 250 kDa	AU = 11 TD = 10	45% low MW bands 55% 250 kDa	Zimmerman <i>et al.</i> (51)	2007
Fetal Human Brain	37 and 73 kDa	AU = 61 DD = 40 TD = 62	12%	Braunschweig <i>et al.</i> (50)	2008
Fetal Human Brain	39 kDa	AU = 84 DD = 49 TD = 160	7%	Croen and Braunschweig (53)	2008
Fetal Human Brain	36 kDa	AU = 100 TD = 100	10%	Singer <i>et al.</i> (52)	2008
Fetal Monkey Brain	37, 39, and 73 kDa	AU = 201 ASD = 71 DD = 102 TD = 185	7% (37 and 73 kDa) 4% (39 and 73 kDa)	Braunschweig <i>et al.</i> (69)	2012
LDH, STIP1, CRMP1, GDA, CRMP2, YBX1	37, 39, 48, 62, and 68 kDa	ASD = 246 TD = 149	7%	Braunschweig <i>et al.</i> (64)	2013
Mouse Brain	Undetermined	ASD = 2431 TD = 653	10.7%	Brimberg <i>et al.</i> (55)	2013

ASD, autism spectrum disorder; AU, autism; CRMP, collapsin response mediator protein; DD, developmental delay; GDA, guanine deaminase; LDH, lactate dehydrogenase; MW, molecular weight; STIP1, stress-induced phosphoprotein 1; TD, typically developing; YBX1, Y-box binding protein 1.

determinants of LDHA, LDHB, CRMP1, and STIP1 to create the most clinically relevant animal model in which to study maternal autoantibody-related autism. Behavioral studies are currently underway in these mice.

AUTOANTIBODIES IN OTHER FORMS OF PSYCHOPATHOLOGY

A number of research groups have established an association with autoimmunity and the presence of anti-brain autoantibodies and the incidence of numerous behavioral disorders (73). Antibodies reactive to neuronal tissues have also been detected in schizophrenia (74–77), Tourette syndrome (78–84), and obsessive-compulsive disorder (85–87), seemingly linking these related and often comorbid disorders. Further, anti-brain autoantibodies have also been observed in children with ASD (88–94). However, unlike the anti-brain autoantibodies observed in mothers of children with autism, the anti-brain antibodies observed in children, and in other disorders, have been found to preferentially bind to adult, rather than fetal, brain substrates, suggesting that they are reactive to a different repertoire of protein targets. The variance in diseases associated with these anti-brain autoantibodies may be due to their antigen specificity and/or the window of exposure by which they interact with their brain-derived protein targets. There is more support for the etiological relevance of fetal brain-reactive maternal antibodies because maternal antibody exposure overlaps major processes in neurodevelopment, and maternal antibodies have greater access to the fetal brain due to increased permissiveness of the blood-brain barrier during gestation (95). In other forms of psychopathology that arise later in life, autoantibodies may still mediate deleterious effects

on the brain leading to aberrations in behavior. Nevertheless, the presence of anti-brain autoantibodies postnatally does not necessarily lead to disorders of brain; it is hypothesized that there must be another event that increases barrier permeability, allowing antibodies to traverse the blood-brain barrier and gain access to brain tissue to inhibit and alter neuronal processes (96,97). However, it may be this necessary preliminary event that accounts for the episodic nature of many psychiatric disorders. Although anti-brain autoantibodies may represent a common etiological agent leading to related psychopathological disorders such as ASD and schizophrenia, there are likely many other aspects, including genetic predisposition, environmental factors, and timing of exposure during development, that contribute to the differing symptoms and manifestations of non-ASD autoantibody-related neuropsychiatric disorders.

CONCLUSIONS

Maternal autoantibody-related ASD has been noted by numerous researchers describing the presence of maternal autoantibodies reactive to fetal brain proteins in a subset of mothers of children with ASD. Further, there is now an abundance of evidence supporting their deleterious role in neurodevelopment. For the most part, these studies have described similar experimental outcomes, and given the clinical and biological heterogeneity of ASD, there likely exists a complex relationship between the presence of maternal anti-fetal brain antibodies and the developmental trajectory of exposed offspring. It is still unclear how and when these maternal autoantibodies arise, but studies currently underway may provide increased insight into their ontogeny. Further, the generation of more

clinically relevant animal models will enable the illumination of the mechanism by which maternal antibodies impair neurodevelopment, resulting in the social and behavioral deficits observed in ASD. Moreover, by determining their mechanism of action, appropriate therapeutic interventions could be implemented, thus raising the optimistic prospect that some future cases of ASD or related neurodevelopmental and psychiatric disorders may be prevented.

ACKNOWLEDGMENTS AND DISCLOSURES

This study was funded by the National Institute of Environmental Health Sciences (NIEHS) Center for Children's Environmental Health and Environmental Protection Agency (Grant Nos. 2P01ES011269-11 and 83543201, respectively, to JV as PI), the NIEHS-funded CHARGE study (Grant No. R01ES015359 to JV and PA as Co-I), and the National Institute of Child Health and Human Development-funded Intellectual and Developmental Disabilities Research Center 054 (Grant No. U54HD079125 to JV as Co-PI).

We thank the staff of the CHARGE study and the families involved in this research.

There are three patents associated with the work at University of California, Davis noted in this review: A provisional 'Maternal Diagnostic Marker for Autism Risk and Therapeutic Intervention' UC Case No. 2014-467-1. There are two issued patents: The US patent Methods of Diagnosing and Treating Autism, U.S. Patent No. 8,383,360 B2 or Pat. 8,383,360 was filed August 12, 2010, and issued February 26, 2013. The client reference number for this patent is 2009-737-2US. This patent is currently in the process of national filing. The first issued patent is Diagnostic Methods for Detection of Autism Spectrum Disorder, U.S. Patent No. US 7,452,681 B2. This patent was filed May 5, 2006, and was issued November 18, 2008. This patent was filed in the United States only. JvDw received consulting fees from Pediatric Bioscience from January 1, 2015, until October 2015. EE and PA report no biomedical financial interests or potential conflicts of interest.

ARTICLE INFORMATION

From the Division of Rheumatology/Allergy and Clinical Immunology (EE, JvDw), The M.I.N.D. Institute (EE, PA, JvDw), NIEHS Center for Children's Environmental Health (PA, JvDw), and Department of Medical Microbiology and Immunology (PA), University of California, Davis, Davis, California.

Address correspondence to Judy Van de Water, Ph.D., Division of Rheumatology/Allergy and Clinical Immunology, 451 E. Health Sciences Dr., Suite 6510, University of California Davis, Davis, CA 95616; E-mail: javandewater@ucdavis.edu.

Received Jun 1, 2016; revised Jul 27, 2016; accepted Aug 24, 2016.

REFERENCES

- American Psychiatric Association, editor (2013): Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association.
- Kanner L (1946): Irrelevant and metaphorical language in early infantile autism. *Am J Psychiatry* 103:242-246.
- Lord C, Risi S, Lambrecht L, Cook EH, Leventhal BL, DiLavore PC, et al. (2000): The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. *J Autism Dev Disord* 30:205-223.
- Newschaffer CJ, Croen LA, Daniels J, Giarelli E, Grether JK, Levy SE, et al. (2007): The epidemiology of autism spectrum disorders. *Annu Rev Public Health* 28:235-258.
- Snow AV, Lecavalier L, Houts C (2009): The structure of the Autism Diagnostic Interview-Revised: diagnostic and phenotypic implications. *J Child Psychol Psychiatry Allied Disciplines* 50:734-742.
- Ousley O, Cermak T (2013): Autism spectrum disorder: Defining dimensions and subgroups. *Curr Dev Disord Rep* 1:20-28.
- McDougle CJ, Landino SM, Vahabzadeh A, O'Rourke J, Zurcher NR, Finger BC, et al. (2015): Toward an immune-mediated subtype of autism spectrum disorder. *Brain Res* 1617:72-92.
- Onore C, Careaga M, Ashwood P (2012): The role of immune dysfunction in the pathophysiology of autism. *Brain Behav Immun* 26:383-392.
- Warren RP, Singh VK, Cole P, Odell JD, Pingree CB, Warren WL, et al. (1991): Increased frequency of the null allele at the complement C4b locus in autism. *Clin Exp Immunol* 83:438-440.
- Warren RP, Odell JD, Warren WL, Burger RA, Maciulis A, Daniels WW, et al. (1996): Strong association of the third hypervariable region of HLA-DRβ1 with autism. *J Neuroimmunol* 67:97-102.
- Torres AR, Sweeten TL, Cutler A, Bedke BJ, Fillmore M, Stubbs EG, Odell D (2006): The association and linkage of the HLA-A2 class I allele with autism. *Hum Immunol* 67:346-351.
- Campbell DB, Li C, Sutcliffe JS, Persico AM, Levitt P (2008): Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder. *Autism Res* 1:159-168.
- Thanseem I, Nakamura K, Miyachi T, Toyota T, Yamada S, Tsujii M, et al. (2010): Further evidence for the role of MET in autism susceptibility. *Neurosci Res* 68:137-141.
- Mostafa GA, Shehab AA (2010): The link of C4B null allele to autism and to a family history of autoimmunity in Egyptian autistic children. *J Neuroimmunol* 223:115-119.
- Jung JY, Kohane IS, Wall DP (2011): Identification of autoimmune gene signatures in autism. *Transl Psychiatry* 1:e63-e63.
- Torres AR, Westover JB, Gibbons C, Johnson RC, Ward DC (2012): Activating killer-cell immunoglobulin-like receptors (KIR) and their cognate HLA ligands are significantly increased in autism. *Brain Behav Immun* 26:1122-1127.
- Comi AM, Zimmerman AW, Frye VH, Law PA, Peeden JN (1999): Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. *J Child Neurol* 14:388-394.
- Atladóttir HO, Pedersen MG, Thorsen P, Mortensen PB, Deleuran B, Eaton WW, et al. (2009): Association of family history of autoimmune diseases and autism spectrum disorders. *Pediatrics* 124:687-694.
- Vinet É, Pineau CA, Clarke AE, Scott S, Fombonne É, Joseph L, et al. (2015): Increased risk of autism spectrum disorders in children born to women with systemic lupus erythematosus: results from a large population-based cohort. *Arthritis Rheum* 67:3201-3208.
- Wu S, Ding Y, Wu F, Li R, Xie G, Hou J, et al. (2015): Family history of autoimmune diseases is associated with an increased risk of autism in children: A systematic review and meta-analysis. *Neurosci Biobehav Rev* 55:322-332.
- Chen S-W, Zhong X-S, Jiang L-N, Zheng X-Y, Xiong Y-Q, Ma S-J, et al. (2016): Maternal autoimmune diseases and the risk of autism spectrum disorders in offspring: A systematic review and meta-analysis. *Behav Brain Res* 296:61-69.
- Chess S (1971): Autism in children with congenital rubella. *J Autism Child Schizophr* 1:33-47.
- Meyer U, Nyffeler M, Engler A, Urwyler A, Schedlowski M, Knuesel I, et al. (2006): The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. *J Neurosci* 26:4752-4762.
- Smith SE, Li J, Garbett K, Mirnics K, Patterson PH (2007): Maternal immune activation alters fetal brain development through interleukin-6. *J Neurosci* 27:10695-10702.
- Atladóttir HÓ, Thorsen P, Østergaard L, Schendel DE, Lemcke S, Abdallah M, et al. (2010): Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. *J Autism Dev Disord* 40:1423-1430.
- Patterson PH (2011): Maternal infection and immune involvement in autism. *Trends Mol Med* 17:389-394.
- Garay PA, Hsiao EY, Patterson PH, McAllister AK (2013): Maternal immune activation causes age- and region-specific changes in brain cytokines in offspring throughout development. *Brain Behav Immun* 31:54-68.
- Ashwood P, Van de Water J (2004): Is autism an autoimmune disease? *Autoimmun Rev* 3:557-562.
- Braunschweig D, Van de Water J (2012): Maternal autoantibodies in autism. *Arch Neurol* 69:693-699.
- Fox E, Amaral D, Van de Water J (2012): Maternal and fetal antibody antibodies in development and disease. *Dev Neurobiol* 72:1327-1334.

Maternal Autoantibodies and Autism

31. Fox-Edmiston E, Van De Water J (2015): Maternal anti-fetal brain IgG autoantibodies and autism spectrum disorder: current knowledge and its implications for potential therapeutics. *CNS Drugs* 29:715–724.
32. Mallampalli MP, Davies E, Wood D, Robertson H, Polato F, Carter CL (2013): Role of environment and sex differences in the development of autoimmune diseases: a roundtable meeting report. *J Women Health* (2002) 22:578–586.
33. Hertz-Picciotto I, Croen LA, Hansen R, Jones CR, van de Water J, Pessah IN (2006): The CHARGE study: an epidemiologic investigation of genetic and environmental factors contributing to autism. *Environ Health Perspect* 114:1119–1125.
34. Christensen DL, Baio J, Van Naarden Braun K, Bilder D, Charles J, Constantino JN, *et al.* (2016): Prevalence of autism spectrum disorders - autism and developmental disabilities monitoring network, 11 sites, United States, 2012. *MMWR Surveill Summ* 65:1–23.
35. Money J, Bobrow NA, Clarke FC (1971): Autism and autoimmune disease: A family study. *J Autism Child Schizophr* 1:146–160.
36. Croen LA, Grether JK, Yoshida CK, Odouli R, Van de Water J (2005): Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: A case-control study. *Arch Pediatr Adolesc Med* 159:151–157.
37. Keil A, Daniels JL, Forssen U, Hultman C, Cnattingius S, Söderberg KC, *et al.* (2010): Parental autoimmune diseases associated with autism spectrum disorders in offspring. *Epidemiology* 21:805–808.
38. Christen U, von Herrath MG (2004): Initiation of autoimmunity. *Curr Opin Immunol* 16:759–767.
39. Ashwood P, Van de Water J (2004): A review of autism and the immune response. *Clin Dev Immunol* 11:165–174.
40. Garay PA, McAllister AK (2010): Novel roles for immune molecules in neural development: Implications for neurodevelopmental disorders. *Front Synaptic Neurosci* 2:136–136.
41. Filiano AJ, Gadani SP, Kipnis J (2015): Interactions of innate and adaptive immunity in brain development and function. *Brain Res* 1617: 18–27.
42. Gluecksohn-Waelsch S (1957): The effect of maternal immunization against organ tissues on embryonic differentiation in the mouse. *Development* 5:83–92.
43. Adinolfi M, Beck SE, Haddad SA, Seller MJ (1976): Permeability of the blood-cerebrospinal fluid barrier to plasma proteins during foetal and perinatal life. *Nature* 259:140–141.
44. Plum F (1981): The concept of a blood-brain barrier. *Ann Neurol* 9: 622–622.
45. Adinolfi M (1985): The development of the human blood-CSF brain barrier. *Dev Med Child Neurol* 27:532–537.
46. Karpiak SE Jr, Rapport MM (1975): Behavioral changes in 2-month-old rats following prenatal exposure to antibodies against synaptic membranes. *Brain Res* 92:405–413.
47. Rick JT, Gregson AN, Leibowitz S, Adinolfi M (1980): Behavioural changes in adult rats following administration of antibodies against brain gangliosides. *Dev Med Child Neurol* 22:719–724.
48. Warren RP, Cole P, Odell JD, Pingree CB, Warren WL, White E, *et al.* (1990): Detection of maternal antibodies in infantile autism. *J Am Acad Child Adolesc Psychiatry* 29:873–877.
49. Dalton P, Deacon R, Blamire A, Pike M, McKinlay I, Stein J, *et al.* (2003): Maternal neuronal antibodies associated with autism and a language disorder. *Ann Neurol* 53:533–537.
50. Braunschweig D, Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Croen LA, *et al.* (2008): Autism: Maternally derived antibodies specific for fetal brain proteins. *Neurotoxicology* 29:226–231.
51. Zimmerman AW, Connors SL, Matteson KJ, Lee LC, Singer HS, Castaneda JA, Pearce DA (2007): Maternal antibody in autism. *Brain Behav Immun* 21:351–357.
52. Singer HS, Morris CM, Gause CD, Gillin PK, Crawford S, Zimmerman AW (2008): Antibodies against fetal brain in sera of mothers with autistic children. *J Neuroimmunol* 194:165–172.
53. Croen LA, Braunschweig D (2008): Maternal mid-pregnancy autoantibodies to fetal brain protein: The early markers for autism study. *Biol Psychiatry* 64:583–588.
54. Heuer L, Braunschweig D, Ashwood P, Van de Water J, Campbell DB (2011): Association of a MET genetic variant with autism-associated maternal autoantibodies to fetal brain proteins and cytokine expression. *Transl Psychiatry* 1:e48.
55. Brimberg L, Sadiq A, Gregersen PK, Diamond B (2013): Brain-reactive IgG correlates with autoimmunity in mothers of a child with an autism spectrum disorder. *Mol Psychiatry* 18:1171–1177.
56. Braunschweig D, Duncanson P, Boyce R, Hansen R, Ashwood P, Pessah IN, *et al.* (2012): Behavioral correlates of maternal antibody status among children with autism. *J Autism Dev Disord* 42: 1435–1445.
57. Nordahl CW, Braunschweig D, Iosif A-M, Lee A, Rogers S, Ashwood P, *et al.* (2013): Maternal autoantibodies are associated with abnormal brain enlargement in a subgroup of children with autism spectrum disorder. *Brain Behav Immun* 30:61–65.
58. Akum BF, Chen M, Gunderson SI, Riefler GM, Scerri-Hansen MM, Firestein BL (2004): Cypin regulates dendrite patterning in hippocampal neurons by promoting microtubule assembly. *Nat Neurosci* 7: 145–152.
59. Lopes MH, Hajj GN, Muras AG, Mancini GL, Castro RM, Ribeiro KC, *et al.* (2005): Interaction of cellular prion and stress-inducible protein 1 promotes neuritogenesis and neuroprotection by distinct signaling pathways. *J Neurosci* 25:11330–11339.
60. Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N, Honnorat J (2003): Collapsin response mediator proteins (CRMPs). *Mol Neurobiol* 28:51–63.
61. Quach TT, Duchemin A-M, Rogemond V, Aguera M, Honnorat J, Belin M-F, *et al.* (2004): Involvement of collapsin response mediator proteins in the neurite extension induced by neurotrophins in dorsal root ganglion neurons. *Mol Cell Neurosci* 25:433–443.
62. Eliseeva IA, Kim ER, Guryanov SG, Ovchinnikov LP, Lyabin DN (2011): Y-box-binding protein 1 (YB-1) and its functions. *Biochemistry (Mosc)* 76:1402–1433.
63. Hashimoto T, Hussien R, Cho H-S, Kaufner D, Brooks GA (2008): Evidence for the mitochondrial lactate oxidation complex in rat neurons: demonstration of an essential component of brain lactate shuttles. *PLoS One* 3:e2915.
64. Braunschweig D, Krakowiak P, Duncanson P, Boyce R, Hansen RL, Ashwood P, *et al.* (2013): Autism-specific maternal autoantibodies recognize critical proteins in developing brain. *Transl Psychiatry* 3:e277.
65. Diamond B, Huerta PT (2009): Losing your nerves? Maybe it's antibodies. *Nat Rev Immunol* 9:449–456.
66. Diamond B, Honig G, Mader S, Brimberg L, Volpe BT (2013): Brain-reactive antibodies and disease. *Annu Rev Immunol* 31:345–385.
67. Martin LA, Ashwood P, Braunschweig D, Cabanlit M, Van de Water J, Amaral DG (2008): Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. *Brain Behav Immun* 22:806–816.
68. Bauman MD, Iosif A-M, Ashwood P, Braunschweig D, Lee A, Schumann CM, *et al.* (2013): Maternal antibodies from mothers of children with autism alter brain growth and social behavior development in the rhesus monkey. *Transl Psychiatry* 3:e278.
69. Braunschweig D, Golub MS, Koenig CM, Qi L, Pessah IN, Van de Water J, *et al.* (2012): Maternal autism-associated IgG antibodies delay development and produce anxiety in a mouse gestational transfer model. *J Neuroimmunol* 252:56–65.
70. Singer HS, Morris C, Gause C, Pollard M, Zimmerman AW, Pletnikov M (2009): Prenatal exposure to antibodies from mothers of children with autism produces neurobehavioral alterations: A pregnant dam mouse model. *J Neuroimmunol* 211:39–48.
71. Camacho J, Jones K, Miller E, Ariza J, Noctor S, Van de Water J, *et al.* (2014): Embryonic intraventricular exposure to autism-specific maternal autoantibodies produces alterations in autistic-like stereotypical behaviors in offspring mice. *Behav Brain Res* 266:46–51.
72. Martínez-Cerdeño V, Camacho J, Fox E, Miller E, Ariza J, Kienzle D, *et al.* (2016): Prenatal exposure to autism-specific maternal autoantibodies alters proliferation of cortical neural precursor cells, enlarges

- brain, and increases neuronal size in adult animals. *Cereb Cortex* 26: 374–383.
73. Benros ME, Eaton WW, Mortensen PB (2014): The epidemiologic evidence linking autoimmune diseases and psychosis. *Biol Psychiatry* 75:300–306.
 74. Heath RG, Krupp IM (1967): Schizophrenia as an immunologic disorder: I. Demonstration of antibrain globulins by fluorescent antibody techniques. *Arch General Psychiatry* 16:1–9.
 75. Patterson PH (2009): Immune involvement in schizophrenia and autism: Etiology, pathology and animal models. *Behav Brain Res* 204: 313–321.
 76. Margari F, Petruzzelli MG, Mianulli R, Campa MG, Pastore A, Tampoia M (2015): Circulating anti-brain autoantibodies in schizophrenia and mood disorders. *Psychiatry Res* 230:704–708.
 77. Margari F, Petruzzelli MG, Mianulli R, Toto M, Pastore A, Bizzaro N, *et al.* (2013): Anti-brain autoantibodies in the serum of schizophrenic patients: A case-control study. *Psychiatry Res* 210:800–805.
 78. Kansy JW, Katsovich L, McIver KS, Pick J, Zabriskie JB, Lombroso PJ, *et al.* (2006): Identification of pyruvate kinase as an antigen associated with Tourette syndrome. *J Neuroimmunol* 181:165–176.
 79. Martino D, Defazio G, Church AJ, Dale RC, Giovannoni G, Robertson MM, *et al.* (2007): Antineuronal antibody status and phenotype analysis in Tourette's syndrome. *Mov Disord* 22:1424–1429.
 80. Murphy TK, Kurlan R, Leckman J (2010): The immunobiology of Tourette's disorder, pediatric autoimmune neuropsychiatric disorders associated with Streptococcus, and related disorders: A way forward. *J Child Adolesc Psychopharmacol* 20:317–331.
 81. Cheng Y-h, Zheng Y, He F, Yang J-h, Li W-b, Wang M-l, *et al.* (2012): Detection of autoantibodies and increased concentrations of interleukins in plasma from patients with Tourette's syndrome. *J Mol Neurosci* 48:219–224.
 82. Elamin I, Edwards MJ, Martino D (2013): Immune dysfunction in Tourette syndrome. *Behav Neurol* 27:23–32.
 83. Hornig M, Lipkin WI (2013): Immune-mediated animal models of Tourette syndrome. *Neurosci Biobehav Rev* 37:1120–1138.
 84. Martino D, Madhusudan N, Zis P, Cavanna AE (2013): An introduction to the clinical phenomenology of Tourette syndrome. *Int Rev Neurobiol* 112:1–33.
 85. Bhattacharyya S, Khanna S, Chakrabarty K, Mahadevan A, Christopher R, Shankar SK (2009): Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. *Neuropsychopharmacology* 34:2489–2496.
 86. Gause C, Morris C, Vernekar S, Pardo-Villamizar C, Grados MA, Singer HS (2009): Antineuronal antibodies in OCD: Comparisons in children with OCD-only, OCD+chronic tics and OCD+PANDAS. *J Neuroimmunol* 214:118–124.
 87. Guiseppe M, Albert U, Bogetto F, Borghese C, Berro AC, Mutani R, *et al.* (2009): Anti-brain antibodies in adult patients with obsessive-compulsive disorder. *J Affect Disord* 116:192–200.
 88. Silva SC, Correia C, Fesel C, Barreto M, Coutinho AM, Marques C, *et al.* (2004): Autoantibody repertoires to brain tissue in autism nuclear families. *J Neuroimmunol* 152:176–182.
 89. Singer HS, Morris CM, Williams PN, Yoon DY, Hong JJ, Zimmerman AW (2006): Antibrain antibodies in children with autism and their unaffected siblings. *J Neuroimmunol* 178:149–155.
 90. Wills S, Cabanlit M, Bennett J, Ashwood P, Amaral D, Van de Water J (2007): Autoantibodies in autism spectrum disorders (ASD). *Ann N Y Acad Sci* 1107:79–91.
 91. Goines P, Haapanen L, Boyce R (2011): Autoantibodies to cerebellum in children with autism associate with behavior. *Brain Behav Immun* 25:514–523.
 92. Morris CM, Zimmerman AW, Singer HS (2009): Childhood serum anti-fetal brain antibodies do not predict autism. *Pediatr Neurol* 41: 288–290.
 93. Cabanlit M, Wills S, Goines P, Ashwood P, Van de Water J (2007): Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder. *Ann N Y Acad Sci* 1107:92–103.
 94. Wills S, Rossi CC, Bennett J, Martinez Cerdeño V, Ashwood P, Amaral DG, *et al.* (2011): Further characterization of autoantibodies to GABAergic neurons in the central nervous system produced by a subset of children with autism. *Mol Autism* 2:1–5.
 95. Kowal C, Athanassiou A, Chen H, Diamond B (2015): Maternal antibodies and developing blood-brain barrier. *Immunol Res* 63:18–25.
 96. Coutinho E, Harrison P, Vincent A (2014): Do neuronal autoantibodies cause psychosis? A neuroimmunological perspective. *Biol Psychiatry* 75:269–275.
 97. Hammer C, Stepniak B, Schneider A, Papiol S, Tantra M, Begemann M, *et al.* (2014): Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. *Mol Psychiatry* 19:1143–1149.